Regeneron Pharma (REGN) PT Lowered to $525 at Morgan Stanley
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $735.20 +0.05%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $525.00 (from $553.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Argus Upgrades Regeneron Pharma (REGN) to Buy, 'attractive entry point '
- Regeneron reports 73% response rate for ubamatamab in ovarian cancer
- Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
